NCT00102505View on ClinicalTrials.gov

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2004

Conditions
Non-Small-Cell Lung CarcinomaCarcinoma, Bronchogenic
Interventions
DRUG

Motexafin Gadolinium Injection

Trial Locations (1)

77030

The University of Texas MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Pharmacyclics LLC.
All Listed Sponsors
lead

Pharmacyclics LLC.

INDUSTRY